AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01816529
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Trial: NCT03907475
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03907475
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01584921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
Trial: NCT01303978
Drug: APD421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00003870
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003870
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01756937
Drug: Imotun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300.03mg/cap,orally, 1 capsule once daily for 24 weeks
Trial: NCT01756937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule once daily for 24 weeks
Trial: NCT00004109
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
Trial: NCT02525523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00047606
Drug: IOP Lowering Medications
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03953820
Drug: Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
Trial: NCT04480736
Drug: JNJ-64281802 Dosing Regimen X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64281802 dosing regimen X will be administered orally.
Trial: NCT04480736
Drug: JNJ-64281802 Dosing Regimen Y
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64281802 dosing regimen Y will be administered orally.
Trial: NCT04480736
Drug: JNJ-64281802 Dosing Regimen Z
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64281802 dosing regimen Z will be administered orally.
Trial: NCT03167905
Drug: Entonox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entonox will be given upon request in non-epidural group.
Trial: NCT03660839
Drug: Ferroquine (SSR97193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT03167905
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Trial: NCT00661141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03329508
Drug: P2B001 0.6/0.75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed low dose extended release combination capsule of pramipexole and rasagiline
Trial: NCT02365207
Drug: BCG strain of Mycobacterium bovis
RxNorm normalized name: Mycobacterium bovis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
Trial: NCT03308578
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Trial: NCT00401778
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
Trial: NCT00969696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8Mg a day of a sugar pill
Trial: NCT00017446
Drug: CP4071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus injection
Trial: NCT00003487
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00515411
Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
Trial: NCT00515411
Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter.
Trial: NCT01658228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
Trial: NCT00006111
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03493607
Drug: AMO-01
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
Trial: NCT00532558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
Trial: NCT00843856
Drug: tacrolimus and mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
Trial: NCT03338972
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03828942
Drug: drug inducing hematological toxicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce hematological toxicities
Trial: NCT03849651
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9
Trial: NCT04341077
Drug: SHR3162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of fluzoparib on Day 1
Trial: NCT05801068
Drug: Factor Xa Inhibitor
RxNorm normalized name: Direct factor Xa inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
Trial: NCT00963131
Drug: antioxidants tablets
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
Trial: NCT00122811
Drug: Indapamide SR 1.5mg; Perindopril 2-4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00099541
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02230800
Drug: Matching placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002711
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03567707
Drug: C-section - Placebo Seeding
RxNorm normalized name: Northside Hospital C-Section Mothers KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
Trial: NCT04205305
Drug: conventional blood pressure control (labetalol, nicardipine)
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
Trial: NCT04205305
Drug: intensive blood pressure control (labetalol, nicardipine)
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
Trial: NCT04231331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo qd for 12 months
Trial: NCT02902081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01651403
Drug: TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.
Trial: NCT00567489
Drug: Physioneal
RxNorm normalized name: Physioneal 40 with 1.36% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physioneal 40 or Physioneal 35
Trial: NCT01534962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, BID; for a maximum of 112 days.
Trial: NCT04752748
Drug: Drug protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48.
Trial: NCT01041833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
Trial: NCT02255799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily for 70 days.
Trial: NCT04025879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01740609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01577680
Drug: Inhaled GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
Trial: NCT00255125
Drug: Soy Supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Trial: NCT00255125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Trial: NCT01837108
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
Trial: NCT01837108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004771
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00672646
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95mg, oral solution, single dose
Trial: NCT00672646
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg, capsule, single dose
Trial: NCT00672646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1386 Placebo oral solution
Trial: NCT01544881
Drug: Technosphere Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder using the Gen2C inhaler
Trial: NCT01544881
Drug: Rapid Acting Analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT03985670
Drug: teripalimab plus chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
Trial: NCT03985670
Drug: chemotherapy plus teripalimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
Trial: NCT00223574
Drug: Control - high carbohydrate, high glycemic index foods
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00223574
Drug: high carbohydrate, low glycemic index foods
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00223574
Drug: low carbohydrate, high monounsaturate fat foods
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01527669
Drug: LipoCol Forte capsules
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Trial: NCT01527669
Drug: Lovastatin Tablet
RxNorm normalized name: Lovastatin Tablets
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Trial: NCT00104234
Drug: N-acetylgalactosamine 4-sulfatase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00104234
Drug: Placebo/rhASB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00703534
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
Trial: NCT00703534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule. administered as a single dose twice daily for 4 weeks
Trial: NCT00703534
Drug: Gelusil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable tablets taken as needed
Trial: NCT02067793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection into the arm on Day 0
Trial: NCT03025594
Drug: Chirocaine ketorolac epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
Trial: NCT01539915
Drug: BCT194
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied BCT194 cream (0.5%)
Trial: NCT00670150
Drug: NRX 195183 (retinoid analogue)
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
Trial: NCT02257736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to apalutamide once daily orally.
Trial: NCT03386448
Drug: placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive placebo medications
Trial: NCT02527005
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tabs Azithromycin 500mg daily for 3 days
Trial: NCT00649025
Drug: FlutiForm 250/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Trial: NCT03970122
Drug: GFB-887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP
Trial: NCT03970122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching
Trial: NCT03657979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP-block with placebo
Trial: NCT02545153
Drug: Tisseel, Baxter (Aprotinin and Fibrinogen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
Trial: NCT01085786
Drug: 14-day sequential treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Trial: NCT01085786
Drug: 14-day hybrid treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Trial: NCT00490516
Drug: ACP-104
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg, tablet, BID, 6 weeks
Trial: NCT00490516
Drug: ACP-104
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, tablet, BID, 6 weeks
Trial: NCT00002989
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03261401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to M5717
Trial: NCT00679432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00679432
Drug: Asacol® 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/day, 400 mg tablets
Trial: NCT04145375
Drug: ZEN003694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 120mg
Trial: NCT00048568
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, \>= 15 mg, weekly, 1 year
Trial: NCT00048568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
Trial: NCT00102635
Drug: SCH66336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
Trial: NCT00864071
Drug: Grifulvin V® 125 mg/5 mL Suspension, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
Trial: NCT01052090
Drug: PHN121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines